Brookstone Capital Management increased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 139.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 239,983 shares of the biopharmaceutical company’s stock after acquiring an additional 139,895 shares during the period. Brookstone Capital Management’s holdings in Pfizer were worth $8,527,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. BancFirst Trust & Investment Management raised its stake in Pfizer by 2.3% in the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 398 shares in the last quarter. Strategic Investment Advisors MI lifted its stake in shares of Pfizer by 32.1% in the 1st quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock valued at $3,840,000 after purchasing an additional 22,879 shares during the period. State of Michigan Retirement System boosted its position in shares of Pfizer by 0.9% during the first quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock valued at $72,281,000 after purchasing an additional 15,900 shares in the last quarter. MainStreet Investment Advisors LLC grew its stake in Pfizer by 1.6% in the first quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock worth $8,057,000 after purchasing an additional 3,099 shares during the period. Finally, Center For Asset Management LLC raised its holdings in Pfizer by 28.0% in the first quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 5,228 shares in the last quarter. 68.05% of the stock is currently owned by institutional investors.
Pfizer Stock Performance
PFE stock opened at $34.07 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 1.82. Pfizer Inc. has a 1 year low of $33.54 and a 1 year high of $54.93. The company has a market cap of $192.36 billion, a P/E ratio of 9.06, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. The stock’s fifty day moving average price is $35.80 and its 200-day moving average price is $37.96.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were given a $0.41 dividend. The ex-dividend date of this dividend was Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.81%. Pfizer’s payout ratio is presently 43.62%.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on PFE. Barclays reduced their target price on shares of Pfizer from $40.00 to $38.00 in a research report on Tuesday, July 11th. Jefferies Financial Group lowered their target price on shares of Pfizer from $40.00 to $38.00 in a report on Wednesday, August 2nd. Morgan Stanley reduced their price objective on Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 2nd. Truist Financial reissued a “buy” rating and issued a $62.00 target price on shares of Pfizer in a report on Wednesday, September 13th. Finally, BMO Capital Markets reduced their price target on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a report on Wednesday, August 2nd. Twelve research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $46.35.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- Financial Services Stocks Investing
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Space Investment: How to Invest in Space Exploration
- MarketBeat Week in Review – 9/11 – 9/15
- What Are Defense Contractor Stocks? How to Invest in Defense
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.